A phase II study of arsenic trioxide in the treatment of relapsed and refractory low-grade lymphomas.

被引：0
|
作者：
Furman, RR [1 ]
Sirulnik, A [1 ]
Kamalu, OO [1 ]
Brenner, RB [1 ]
Paciucci, PA [1 ]
Gabrilove, JL [1 ]
Waxman, S [1 ]
机构：
[1] Mt Sinai Sch Med, Div Hematol & Oncol, New York, NY USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4758
引用
收藏
页码：304B / 304B
页数：1
相关论文
共 50 条
  • [41] Thalidomide use in patients with relapsed, refractory, low-grade lymphoma
    Lowenthal, EA
    Camp-Sorrell, LD
    Lingenfelter, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 600S - 600S
  • [42] Bendamastine/mitoxantrone/rituximab (BMR): A new effective treatment for refractory or relapsed indolent lymphomas.
    Weide, R
    Heymanns, J
    Pandorf, A
    Koeppler, H
    BLOOD, 2002, 100 (11) : 572A - 572A
  • [43] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    BLOOD, 2000, 96 (11) : 236B - 236B
  • [44] Bendamustine mitoxantrone rituximab (BMR):: A new effective treatment for refractory or relapsed indolent lymphomas.
    Weide, R
    Heymanns, J
    Pandorf, A
    Köppler, H
    BLOOD, 2001, 98 (11) : 253B - 253B
  • [45] Treatment of Elderly and Relapsed/Refractory AML Patient Using Cytosar and Arsenic Trioxide
    Eslamijouybari, Mohammad
    Ghavamzadeh, Ardeshir
    Alimoghaddam, Kamran
    Vaezi, Mohammad
    Yaghmaie, Marjan
    BLOOD, 2017, 130
  • [46] The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review
    Roellig, Christoph
    Illmer, Thomas
    CANCER TREATMENT REVIEWS, 2009, 35 (05) : 425 - 430
  • [47] Bendamustin in combination with Fludarabin for the treatment of refractory or relapsed low-grade lymphoma - A multicenter phase I/II trial of the East German study group for hematology and oncology (OSHO).
    Koenigsmann, MP
    Knauf, WU
    Herold, M
    Franke, A
    BLOOD, 2001, 98 (11) : 607A - 607A
  • [48] SINGLE AGENT BORTEZOMIB IS ACTIVE IN RELAPSED/REFRACTORY MALT LYMPHOMAS. FINAL RESULTS OF AN INTERNATIONAL EXTRAODAL LYMPHOMA STUDY GROUP (IELSG) PHASE II STUDY
    Conconi, A.
    Martinelli, G.
    Lopez-Guillermo, A.
    Zinzani, P. L.
    Ferreri, A.
    Rigacci, L.
    Devizzi, L.
    Vitolo, U.
    Luminari, S.
    Martelli, M.
    Cavalli, F.
    Zucca, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 419 - 419
  • [49] Bendamustine/mitoxantrone/rituximab (BMR):: A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas.: Results of a multicentre phase-II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide, R
    Heymanns, J
    Thomalla, J
    Köppler, H
    Hess, G
    Aldaoud, A
    Schmitz, S
    Unterhalt, M
    Dreyling, MH
    Hiddemann, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 589S - 589S
  • [50] A phase I/II multicenter, safety and efficacy study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) in patients with relapsed or refractory multiple myeloma
    Berenson, JR
    BLOOD, 2004, 104 (11) : 659A - 659A
12345